

# SUBMITTED ABSTRACTS

**7<sup>TH</sup> ANNUAL MEETING**

**NEW TECHNOLOGIES  
AND STRATEGIES  
TO FIGHT CANCER**

**ROME**

**September 21-23, 2022**

Fondazione Policlinico Gemelli IRCCS  
Università Cattolica del Sacro Cuore



ALLIANCE  
AGAINST  
CANCER

## SUBMITTED ABSTRACTS

SEPTEMBER 21 <sup>st</sup>				
<b>P.01</b>	<b>Roman</b>	<b>Celia</b>	Regina Elena National Cancer Institute, Roma	Impacting on tumor-stroma crosstalk by targeting endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition
<b>P.02</b>	<b>Albano</b>	<b>Francesco</b>	Centro di Riferimento Oncologico della Basilicata, IRCCS, Rionero in Vulture, Potenza	Identification of a novel gastric cancer microenvironment master regulator
<b>P.03</b>	<b>Andreone</b>	<b>Sara</b>	Istituto Superiore di Sanità, Roma	Eosinophils acquire immune checkpoint molecules through trogocytosis: implications in cancer immunity
<b>P.04</b>	<b>Ciccone</b>	<b>Roselia</b>	Pediatric Hospital Bambino Gesù, Roma	CAR.GD2 T cells containing CD28.41BB costimulatory domains as a powerful adoptive T cell therapy for patients with GD2 + medulloblastoma
<b>P.05</b>	<b>Di Modugno Damiani</b>	<b>Francesca Romana</b>	IRCCS Regina Elena National Cancer Institute, Roma	Tumoral and stromal hMENA isoforms influence tertiary lymphoid structure localization and predict response to immunecheckpoint blockade in lung cancer patients
<b>P.06</b>	<b>Failla</b>	<b>Cristina</b>	Istituto Dermatologico dell' Immacolata IRCCS, Roma	Development of skin leukoderma in melanoma patients after treatment with checkpoint inhibitors gives insight into the raising of an effective anti-tumor immune response
<b>P.07</b>	<b>Gambardella</b>	<b>Adriana Rosa</b>	Istituto Superiore di Sanità Roma	Eosinophils and Interleukin-33 -mediated anticancer activities: role of exosomes in shaping tumor phenotype
<b>P.08</b>	<b>Ieranò</b>	<b>Caterina</b>	Molecular Microenvironment Targets, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale" - IRCCS, Napoli	Crosstalk between Chemokine Receptor CXCR4 and Intrinsic Programmed Cell Death-1 PD-1: PD-1 promotes CXCL12 cell migration in colon cancer cells
<b>P.09</b>	<b>Lucarini</b>	<b>Valeria</b>	Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, Roma	Combined treatment with mitoxantrone and TGFβ and PD-1 blockade remodels the tumor immune landscape by enhancing neuroblastoma antitumor immunity
<b>P.10</b>	<b>Melaiu</b>	<b>Ombretta</b>	Immuno-Oncology Laboratory, Department of Haematology and Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Roma	Prognostic role of B cells and Tertiary Lymphoid Structures in patients with neuroblastoma
<b>P.11</b>	<b>Melchionna</b>	<b>Roberta</b>	IRCCS- Regina Elena National Cancer Institute, Roma	hMENA regulates TGF-β signalling in cancer associated fibroblasts of NSCLC patients and contributes to TGF-β-mediated immunosuppression by regulating PD-L1/PD-1 axis
<b>P.12</b>	<b>Meotto</b>	<b>Diana</b>	Promega Italia s.r.l., Milano	Quantitative cell-based reporter gene bioassays to advance individual or combination cancer immunotherapy
<b>P.13</b>	<b>Palermo</b>	<b>Belinda</b>	IRCCS Regina Elena National Cancer Institute, Roma	Multiparametric flow-cytometry and single-cell RNA sequencing reveal a fine-tuned balance between CD28 and co-stimulatory/co-inhibitory receptors, which affects CD8+T cell functionality in periphery versus tumor site and clinical outcome of NSCLC patients
<b>P.14</b>	<b>Pezzella</b>	<b>Michele</b>	Department of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children Hospital, IRCCS, Roma	Engineering CXCR2-modified GD2.CAR T Cells to improve chemotaxis and antitumor efficacy in a pediatric osteosarcoma model
<b>P.15</b>	<b>Potenza</b>	<b>Alessia</b>	IRCCS San Raffaele Scientific Institute, Milano	Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells
<b>P.16</b>	<b>Spiga</b>	<b>Martina</b>	Ospedale San Raffaele, Milano	Cytosine base editor enhances T cell therapy for gastrointestinal cancers
<b>P.17</b>	<b>Santagata</b>	<b>Sara</b>	Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Napoli	Inhibition of CXCR4 impaired Tregs function in primary renal cancer patients targeting PTEN signaling

<b>P.18</b>	<b>Silvestris</b>	<b>Domenico Alessandro</b>	Ospedale Pediatrico Bambino Gesù, Roma	Mechanisms of in vivo CAR.CD19-T cell expansion and persistence: transcriptomic characterization by single-cell mRNA analysis
<b>P.19</b>	<b>Presta</b>	<b>Francesco</b>	Fondazione Policlinico Agostino Gemelli IRCCS, Roma	HTA and Artificial Intelligence: Evaluation, analysis and Impact for the hospital context
<b>P.20</b>	<b>Supino</b>	<b>Domenico</b>	Humanitas Clinical and Research Center-IRCCS, Milano	IL-1R8 regulates the anti-tumor potential of CD8+ T cells acting as an immune checkpoint
<b>P.21</b>	<b>Tazzari</b>	<b>Marcella</b>	IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola	Activity assessment of GD2 CAR-T in preclinical 3D models of metastatic melanoma
<b>P.22</b>	<b>Trippitelli</b>	<b>Federica</b>	Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano	Drug treatment of ovarian cancer cells modulates the expression of immune-related molecules
<b>P.23</b>	<b>Trotta</b>	<b>Anna Maria</b>	Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Napoli	Development of 68Ga-labeled R54-Dendrimer: a new PET imaging probes targeting CXCR4 for cancer cells and tumor microenvironment
<b>P.24</b>	<b>Tumedei</b>	<b>Maria Maddalena</b>	IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola	Follicular lymphoma microenvironment traits associated with disease recurrence
<b>P.25</b>	<b>Valvano</b>	<b>Luciana</b>	Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB)	Double Negative T (DNT) cells in B-chronic lymphocytic leukemia: a potential immune surveillance overseer
<b>P.26</b>	<b>Bergamaschi</b>	<b>Luca</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Role of radiotherapy in platinum-sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment
<b>P.27</b>	<b>Giudice</b>	<b>Maria Teresa</b>	Fondazione Policlinico Agostino Gemelli IRCCS, Roma	Deep learning predicts somatic BRCA 1/2 genes mutational status from histopathology of epithelial ovarian cancer: A hypothesis generating study
<b>P.28</b>	<b>Marini</b>	<b>Bruna</b>	Ulisse BioMed, Trieste	Self-collection for cervical cancer prevention: clinical validation of full genotyping HPV Selfy assay according to the international guidelines screening
<b>P.29</b>	<b>Mastrantonio</b>	<b>Roberta</b>	Department of Life Sciences and Public Health, Section of Histology and Embryology, UCSC, Roma; Fondazione Policlinico Agostino Gemelli , IRCCS, Roma	Semaphorin4C is implicated in oxidative stress regulation: a new way to counteract the chemotherapeutic resistance in ovarian cancer
<b>P.30</b>	<b>Pisanu</b>	<b>Maria Elena</b>	Istituto Superiore di Sanità, NMR Unit, Core Facilities, Roma	A pilot study on integration of multiomics-based approaches to discover novel biological traits associated with chemotherapy response
<b>P.31</b>	<b>Tassi</b>	<b>Elena</b>	IRCCS Ospedale San Raffaele, Milano	Epithelial Ovarian Cancer is infiltrated by activated effector T cells co-expressing multiple inhibitory receptors and by myeloid cells expressing inhibitory receptor ligands
<b>P.32</b>	<b>Arena</b>	<b>Sabrina</b>	Candiolo Cancer Institute- IRCCS, Candiolo; Department of Oncology University of Torino	Targeting the DNA damage response and replication stress as a new therapeutic opportunity in colorectal cancer
<b>P.33</b>	<b>Bazzichetto</b>	<b>Chiara</b>	IRCCS Regina Elena National Cancer Institute, Roma	A systematic review and meta-analysis of the prognostic impact of interleukin-8 in colorectal cancer patients
<b>P.34</b>	<b>Cascianelli</b>	<b>Silvia</b>	Politecnico di Milano	Statistical and machine learning methods to investigate mutations in RAS-mutated colorectal cancer patients
<b>P.35</b>	<b>Cascianelli</b>	<b>Silvia</b>	Politecnico di Milano	Gene expression-based multi-label classification to face colorectal cancer heterogeneity and provide biologically and clinically relevant traits
<b>P.36</b>	<b>Cecchin</b>	<b>Erika</b>	Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano	Somatic variants in RAS/RAF/SMAD4 in pre-treatment biopsies identify LARC patients at risk of poor response and high tumor recurrence risk

## SUBMITTED ABSTRACTS

<b>P.37</b>	<b>Colella</b>	<b>Filomena</b>	Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma	Metachromin V from a marine sponge as potential therapeutic drug in colorectal cancer
<b>P.38</b>	<b>Dal Buono</b>	<b>Arianna</b>	Department of Gastroenterology, Humanitas Research Hospital - IRCCS, Rozzano, Milano	Next-generation sequencing analysis of primary colorectal cancer lesions and paired distant metastases: a retrospective study
<b>P.39</b>	<b>Damato</b>	<b>Angela</b>	Azienda USL - IRCCS Reggio Emilia	FOLFOXIRI/bevacizumab (BEV) plus Nivolumab (NIV) as first-line (1L) therapy in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients (pts), regardless of microsatellite status: Results of phase II NIVACOR Trial
<b>P.40</b>	<b>Fasano</b>	<b>Candida</b>	National Institute for Gastroenterology, IRCCS 'S. de Bellis' Research Hospital, Castellana Grotte, Bari	Identifying novel SMYD3 interactors on the trail of cancer hallmarks
<b>P.41</b>	<b>Fiore</b>	<b>Alessia</b>	Istituto Superiore di Sanità, Roma	Exploring the tumor-promoting potential of the Escherichia coli toxin CNF1: a preclinical study
<b>P.42</b>	<b>Forte</b>	<b>Giovanna</b>	National Institute of Gastroenterology "S. de Bellis" Research Hospital, Castellana Grotte, Bari	Coinheritance of Germline Mutations in APC and MUTYH in italian family with colorectal adenomatous polyposis
<b>P.43</b>	<b>Grossi</b>	<b>Valentina</b>	National Institute for Gastroenterology, IRCCS 'S. de Bellis' Research Hospital, Castellana Grotte, Bari	A novel STK11 gene mutation (c.388dupG, p.Glu130Glyfs*33) in a Peutz-Jeghers family and evidence of higher gastric cancer susceptibility associated with alterations in STK11 region aa 107-170
<b>P.44</b>	<b>Lucchetti</b>	<b>Donatella</b>	Dipartimento di Medicina e Chirurgia traslazionale-Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Roma;	Role of CD147-mediated exosome-cell interaction in tumor microenvironment
<b>P.45</b>	<b>Notarnicola</b>	<b>Maria</b>	National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari	Effects of grape intake on circulating microRNAs levels involved in colorectal cancer-related pathways
<b>P.46</b>	<b>Scavo</b>	<b>Maria Principia</b>	Personalized Medicine Laboratory, National Institute of Gastroenterology "Saverio de Bellis" Research Hospital, Castellana Grotte, Bari	Exosome released FZD10 increases Ki-67 expression via phospho-ERK1/ 2 in colorectal cancer
<b>P.47</b>	<b>Scavo</b>	<b>Maria Principia</b>	Personalized Medicine Laboratory, National Institute of Gastroenterology "Saverio de Bellis" Research Hospital, Castellana Grotte, Bari	Activation of the epithelial-mesenchymal transition induced by exosomes derived from colon metastatic cancer cell line on colon, hepatic and pancreatic normal cell lines
<b>P.48</b>	<b>Scialpi</b>	<b>Rosanna</b>	IRCCS Saverio de Bellis-Ospedale Specializzato in Gastroenterologia, Castellana Grotte, Bari	Inorganic polyphosphate promotes CRC progression via TRPM8 receptor
<b>P.49</b>	<b>Serino</b>	<b>Grazia</b>	National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari	Identification of a a gene-based machine learning classifier associated to the colorectal adenoma-carcinoma sequence
<b>P.50</b>	<b>Corrao</b>	<b>Giulia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Upfront advanced radiotherapy and new drugs for advanced NSCLC patients with synchronous brain metastases: is the juice worth the squeeze? A real-world analysis from Lombardy
<b>P.51</b>	<b>Zaffaroni</b>	<b>Mattia</b>	Department of Clinical and Molecular Medicine, Sapienza Università di Roma	Multiomic analysis reveals ALDOC and ENO2 as master regulators of lung Cancer Stem Cells metabolism
<b>P.52</b>	<b>Finocchiaro</b>	<b>Domenico</b>	Azienda USL di Reggio Emilia	Development of an automatic tool for treatment optimization in 3D Spatially Fractionated Radiation Therapy
<b>P.53</b>	<b>Genova</b>	<b>Carlo</b>	UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova; Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova	Deep molecular characterization of Never Smoker Non-Small-Cell Lung cancer patients
<b>P.54</b>	<b>Lazzari</b>	<b>Chiara</b>	Candiolo Cancer Institute, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS	Preliminary results from the ACC lung cohort study: a circulating tumor DNA (ctDNA) analysis of NSCLC patients
<b>P.55</b>	<b>Mazzarelli</b>	<b>Francesco</b>	Cancer Biomarkers Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo	Analysis of extracellular-vesicle miRNAs in a new aggressive molecular subtype of lung cancer

<b>P.56</b>	<b>Melocchi</b>	<b>Valentina</b>	Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo	Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype
<b>P.57</b>	<b>Raimondi</b>	<b>Sara</b>	European Institute of Oncology, Milano	Association between contrast-enhanced CT radiomic features and prognosis in advanced non-small cell lung cancer patients
<b>P.58</b>	<b>Sceni</b>	<b>Giada</b>	Specialization School in Medical Physics, University of Bologna, Medical Physics Unit, AUSL-IRCCS di Reggio Emilia	Radcalc 3D Monte Carlo: a new independent calculation-based approach to improve plan dose verification for lung radiotherapy
<b>P.59</b>	<b>Testa</b>	<b>Erika</b>	Policlinico Gemelli IRCCS, Roma	Neuropilin-2 affects the EMT process in A549 cell by controlling TGFβ/EGF signaling pathways
<b>P.60</b>	<b>Torricelli</b>	<b>Federica</b>	Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia	Resolving histological heterogeneity by morphology guided digital spatial profiling provides new clues to rationalize immunotherapy application in malignant pleural mesothelioma (MPM)
<b>P.61</b>	<b>D'Alessandris</b>	<b>Quintino Giorgio</b>	Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma	A study of clinical and molecular prognostic factors for response to regorafenib in recurrent glioblastoma.
<b>P.62</b>	<b>Diaz Mendez</b>	<b>Ana Belen</b>	IRCCS Regina Elena National Cancer Institute, Roma	A diagnostic circulating miRNA signature as orchestrator of cell invasion via TKS4/TSK5 modulation in human gliomas
<b>P.63</b>	<b>Faletti</b>	<b>Stefania</b>	Istituto Europeo di Oncologia, Milano	Targeting LSD1 scaffolding function to counteract glioblastoma adaptation to cellular stress
<b>P.64</b>	<b>Iorio</b>	<b>Egidio</b>	Istituto Superiore di Sanità, Roma	Metabolomic approaches using 1H NMR spectroscopy detect multiple metabolic targets for the antitumor action of metformin on human glioma cells
<b>P.65</b>	<b>Lazzarini</b>	<b>Elisabetta</b>	Istituto Oncologico Veneto - IRCCS, Padova	Genome-wide profiling of glioblastoma-derived cell lines reveals recurrent genetic alterations and transcriptomic signatures associated with brain tumors
<b>P.66</b>	<b>Miele</b>	<b>Evelina</b>	Bambino Gesù Children's Hospital, IRCCS, Roma	5-year GBM survivors: clinico-radiological and pathological features and molecular characterization by genome-wide DNA methylation profiling and genetic sequencing of a large Italian cohort
<b>P.67</b>	<b>Orzan</b>	<b>Francesca</b>	Candiolo Cancer Institute, FPO-IRCCS	Liquid biopsy of cerebrospinal fluid enables targeted genetic profiling for glioblastoma identification at clinical presentation
<b>P.68</b>	<b>Vinci</b>	<b>Maria</b>	Ospedale Pediatrico Bambino Gesù, Roma	Abrogation of exosome biogenesis significantly affects cell motility in heterogeneous sub-populations of paediatric-type diffuse high-grade glioma
<b>SEPTEMBER 22<sup>nd</sup></b>				
<b>P.01</b>	<b>Albasini</b>	<b>Sara Paola</b>	Breast Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia	Deep learning based pipeline for automatic classification of breast microcalcifications
<b>P.02</b>	<b>Zaffaroni</b>	<b>Mattia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Partial breast re-irradiation with IMRT for local recurrence after whole breast radiotherapy
<b>P.03</b>	<b>Aricò</b>	<b>Eleonora</b>	Istituto Superiore di Sanità, Roma	Metabolic reprogramming during spontaneous mammary tumor development and progression in HER2/neu transgenic mice: a role for endogenous type I Interferon
<b>P.04</b>	<b>Baldazzi</b>	<b>Davide</b>	Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano - IRCCS, Aviano	DElite: A Tool for Integrated Differential Expression analysis

## SUBMITTED ABSTRACTS

<b>P.05</b>	<b>Belletti</b>	<b>Barbara</b>	Centro di Riferimento Oncologico di Aviano	Capturing tumor heterogeneity to personalize therapy in young luminal breast cancer patients
<b>P.06</b>	<b>Bimonte</b>	<b>Sabrina</b>	Istituto Nazionale Tumori – IRCCS - "Fondazione G. Pascale", Napoli	The inhibitory effects of Propofol and (-)-Epigallocatechin-3-gallate on the growth of triple negative breast cancer cells.
<b>P.07</b>	<b>Bove</b>	<b>Samantha</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	Analyzing Invasive Disease Event prediction through an Explainable Artificial Intelligence approach
<b>P.08</b>	<b>Cardinali</b>	<b>Barbara</b>	IRCCS Ospedale Policlinico San Martino, Genova	Genomic test aiming to identify actionable mutations in Hormone Receptor -/ HER2+ or triple negative breast cancer (NEOGENE Trial) - Study Update
<b>P.09</b>	<b>Coppola</b>	<b>Luigi</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	Identification of immune cells components in breast tissues by a multiparametric flow cytometry approach
<b>P.10</b>	<b>D'Ecclesiis</b>	<b>Oriana</b>	European Institute of Oncology, Milano	Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with MRI-Radiomics: a systematic review and meta-analysis
<b>P.11</b>	<b>Zaffaroni</b>	<b>Mattia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Upfront stereotactic radiotherapy with Cyberknife for HER2+ breast cancer patients: update of monoinstitutional experience with 82 metachronous brain metastases
<b>P.12</b>	<b>Zaffaroni</b>	<b>Mattia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Plan quality comparison at five years in two cohorts of breast cancer patients treated with Helical Tomotherapy
<b>P.13</b>	<b>Ferrara</b>	<b>Paola Emilia</b>	Degenza e Servizi di Riabilitazione Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; Università Cattolica del Sacro Cuore, Roma	A retrospective analysis of the effects of the early rehabilitation after breast cancer surgery
<b>P.14</b>	<b>Franceschi</b>	<b>Silvia</b>	Direzione Scientifica, IRCCS Centro di Riferimento Oncologico di Aviano	De-implementation of axillary staging and post-lumpectomy radiotherapy in low-risk breast cancer patients aged 70-79 from six National Cancer Institutes in Italy
<b>P.15</b>	<b>Gaeta</b>	<b>Aurora</b>	Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milano	Women's perceptions and attitudes to the use of AI in breast cancer screening: a survey in a cancer referral center
<b>P.16</b>	<b>Magnavita</b>	<b>Nicola</b>	Policlinico Agostino Gemelli, Roma	Back to work. A program for women with breast cancer
<b>P.17</b>	<b>Mangone</b>	<b>Lucia</b>	Epidemiology Unit, AUSL-IRCCS Reggio Emilia	The impact of COVID-19 on new cancer diagnoses in a northern Italian province
<b>P.18</b>	<b>Massafra</b>	<b>Raffaella</b>	IRCCS Istituto Tumori "Giovanni Paolo II", Bari	An invasive disease event free survival analysis for investigating the role of Ki67 in breast cancer patients of different ages
<b>P.19</b>	<b>Noberini</b>	<b>Roberta</b>	Istituto Europeo di Oncologia, Milano	A multi-OMICs approach to dissect aberrant epigenetic mechanisms in triple negative breast cancer
<b>P.20</b>	<b>Paroni</b>	<b>Gabriela</b>	Istituto di Ricerche Farmacologiche Mario Negri, Mialno	The role of orphan nuclear receptors in breast cancer cell proliferation
<b>P.21</b>	<b>Vincini</b>	<b>Maria Giulia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy - An airo multi institutional study
<b>P.22</b>	<b>Piccotti</b>	<b>Francesca</b>	Istituti Clinici Scientifici Maugeri IRCCS, Pavia	Preoperative systemic inflammatory biomarkers predict disease relapse in early breast cancer
<b>P.23</b>	<b>Saponaro</b>	<b>Concetta</b>	IRCCS- Istituto tumori "Giovanni Paolo II", Bari	Role of NDRG1 in invasive luminal and triple negative breast carcinoma
<b>P.24</b>	<b>Signati</b>	<b>Lorena</b>	University of Milan	Breast cancer Patient-derived Organoids (PDO) in personalized medicine approaches: a case study
<b>P.25</b>	<b>Valentini</b>	<b>Virginia</b>	Department of Molecular Medicine, Sapienza University of Rome	Molecular tumor profiling in male breast cancer by targeted gene panel sequencing

<b>P.26</b>	<b>Zaffaroni</b>	<b>Mattia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	Halfmoon radiotherapy: A real-world experience in a single institution
<b>P.27</b>	<b>Bonizzi</b>	<b>Giuseppina</b>	Division of Pathology, IRCCS European Institute of Oncology, Milano	Biobank in Breast Cancer: 10 years of practice at the European Institute of Oncology
<b>P.28</b>	<b>Allegretti</b>	<b>Matteo</b>	IRCCS Regina Elena National Cancer Institute, Roma	Liquid biopsy and Trastuzumab Emfansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients
<b>P.29</b>	<b>Artemi</b>	<b>Giulia</b>	Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma	Prognostic and predictive significance of selected cytokines in serum of metastatic colorectal cancer (mCRC)
<b>P.30</b>	<b>Brisotto</b>	<b>Giulia</b>	Immunopathology and Cancer Biomarkers Units, Department of Translational Research, Centro di Riferimento Oncologico di Aviano	Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients
<b>P.31</b>	<b>Campo</b>	<b>Flaminia</b>	Department Otolaryngology Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri, Roma	Study of viral Biomarkers and microRNAs in HPV-associated Oropharyngeal cancer and Cancer of Unknown Primary
<b>P.32</b>	<b>Coco</b>	<b>Simona</b>	Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova	Prognostic role of circulating PD-L1, B7H3 and B7H4 in patients with Non-Small Cell Lung Cancer treated with immune checkpoint inhibitors
<b>P.33</b>	<b>Costantini</b>	<b>Susan</b>	Istituto Nazionale Tumori "Fondazione Giovanni Pascale", IRCCS, Napoli	Untargeted NMR-based metabolomics approach to identify novel prognostic and predictive biomarkers in cancer patients
<b>P.34</b>	<b>Marchini</b>	<b>Sergio</b>	Humanitas Research Hospital- IRCCS, Milano	Exploiting sWGS analysis of plasma DNA to predict patient's outcome for HGS-EOC: the MITO-16a/MANGO-OV2a/ experience
<b>P.35</b>	<b>Palazzo</b>	<b>Claudia</b>	Policlinico Agostino Gemelli, Roma	Exosomes released by tumor cells mediate a new Neupilin-dependent mechanism of endothelial cell regulation
<b>P.36</b>	<b>Paolini</b>	<b>Francesca</b>	IRCCS Regina Elena National Cancer Institute, Roma	Observational study to evaluate the prognostic significance of a specific HPV-16 E5 mRNA on HPV-associated oropharyngeal cancer
<b>P.37</b>	<b>Paterra</b>	<b>Rosina</b>	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano	Cell-free DNA (cfDNA)-based liquid biopsy of cerebrospinal fluid (CSF) in brain cancer
<b>P.38</b>	<b>Pieri</b>	<b>Valentina</b>	Neurology Unit, IRCCS San Raffaele Scientific Institute, Milano	Plasma cfDNA liquid biopsy in the follow-up of high-grade gliomas
<b>P.39</b>	<b>Virga</b>	<b>Alessandra</b>	Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola	Tailored therapies for prostate cancer patients: multi-genes panel characterization of homologous recombination system and shallow WGS on liquid biopsy
<b>P.40</b>	<b>Zaccheroni</b>	<b>Elena</b>	European Institute of Oncology IRCCS, Milano	Circulating plasma extracellular vesicles: A novel approach to advance the diagnosis and monitoring of patients with glioblastoma
<b>P.41</b>	<b>Avesani</b>	<b>Giacomo</b>	Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma	CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset
<b>P.42</b>	<b>Bellerba</b>	<b>Federica</b>	European Institute of Oncology, Milano	Radiomic analysis of pre-surgery FDG-PET images in early stage Non Small Lung Cancer patients can improve overall survival prediction
<b>P.43</b>	<b>Bertolini</b>	<b>Marco</b>	Azienda USL-IRCCS di Reggio Emilia	Impact of a novel harmonization method in prognostic predictive power of radiomic analysis for multi-centric radiomic studies in Non-Small Cell Lung Cancer
<b>P.44</b>	<b>Bove</b>	<b>Samantha</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	Ultrasound-based radiomics for predicting sentinel lymph-node metastasis in clinically negative breast cancer patients
<b>P.45</b>	<b>Brancato</b>	<b>Valentina</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	The relationship between radiomics and pathomics in Glioblastoma patients: preliminary results from a cross-scale association study
<b>P.46</b>	<b>Brancato</b>	<b>Valentina</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	Development and evaluation of an automatic approach for identification and assessment of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer

## SUBMITTED ABSTRACTS

<b>P.47</b>	<b>Brancato</b>	<b>Valentina</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	<a href="#">Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesion</a>
<b>P.48</b>	<b>Castaldo</b>	<b>Rossana</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	<a href="#">Defining normalization standards for quantitative radiomic features to enable phenotypic profiling of tumours</a>
<b>P.49</b>	<b>Comes</b>	<b>Maria Colomba</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	<a href="#">Early prediction of neoadjuvant chemotherapy response by means of a transfer learning approach performed on breast DCE-MRIs</a>
<b>P.50</b>	<b>Donati</b>	<b>Benedetta</b>	Azienda USL-IRCCS di Reggio Emilia	<a href="#">Prognostic value of lesion dissemination (Dmax) in classica Hodgkin Lymphoma (cHL) assessed by a radiogenomic approach</a>
<b>P.51</b>	<b>Fanizzi</b>	<b>Annarita</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	<a href="#">Robustness Evaluation of a deep learning model on Sagittal and Axial DCE-MRIs to predict pathological complete response in breast cancer patients undergoing neoadjuvant chemotherapy</a>
<b>P.52</b>	<b>Fanizzi</b>	<b>Annarita</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	<a href="#">Radiomic signature from baseline CT scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma. Preliminary data</a>
<b>P.53</b>	<b>Vincini</b>	<b>Maria Giulia</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano	<a href="#">Radiomic feature relevance in the prediction of pathological features of prostate cancer</a>
<b>P.54</b>	<b>Marturano</b>	<b>Francesca</b>	Istituto Oncologico Veneto - IRCCS, Padova	<a href="#">Prediction of biochemical recurrence in intermediate-high risk prostate cancer (PCa) patients from staging 18F-Choline (FCh)-PET/CT: a radiomic-based approach</a>
<b>P.55</b>	<b>Vincini</b>	<b>Maria Giulia</b>	Division of Radiation Oncology, European Institute of Oncology, IRCCS, Milano; Department of Oncology and Hemato-Oncology, University of Milan	<a href="#">Added value of MRI radiomics to predict pathological status of prostate cancer patients</a>
<b>P.56</b>	<b>Massafra</b>	<b>Raffaella</b>	IRCCS Istituto Tumori "Giovanni Paolo II", Bari	<a href="#">Radecision ACC project - Radiomic analysis for predicting late xerostomia after radiotherapy in oropharyngeal cancer patients</a>
<b>P.57</b>	<b>Mastroleo</b>	<b>Federico</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano; Department of Translational Medicine, University of Piemonte Orientale, Novara	<a href="#">Process mining: a new approach for improving patients' care path in high volume radiation oncology department</a>
<b>P.58</b>	<b>Mastroleo</b>	<b>Federico</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano; Department of Translational Medicine, University of Piemonte Orientale, Novara	<a href="#">Quo vadis, radiomics? Bibliometric analysis of 10-year radiomics journey</a>
<b>P.59</b>	<b>Morelli</b>	<b>Letizia</b>	Department of Electronics, Information and Bioengineering (DEIB), POLIMI, Milano	<a href="#">Radiomics in diffusion MRI for localized prostate cancer characterization (AIRC IG - 24946)</a>
<b>P.60</b>	<b>Piccinini</b>	<b>Filippo</b>	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola	<a href="#">DS4H Image Alignment: a user-friendly ImageJ/Fiji plugin for analysing multimodality/IHC/IF 2D microscopy images</a>
<b>P.61</b>	<b>Triumbari</b>	<b>Elizabeth</b>	Unit of Nuclear Medicine, TracerGLab, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma	<a href="#">Classical Hodgkin's Lymphoma: does baseline 18F-FDG PET/CT radiomics from the largest and hottest lesions add value to conventional prognostic models?</a>
<b>P.62</b>	<b>Volpe</b>	<b>Stefania</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano; Department of Oncology and Hemato-Oncology, University of Milan	<a href="#">Impact of image filtering and assessment of volume-confounding effects on CT radiomic features and derived survival models in NSCLC back to basics in the era of radiomics: an explorative study on the Lung-1 dataset</a>
<b>P.63</b>	<b>Volpe</b>	<b>Stefania</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano; Department of Oncology and Hemato-Oncology, University of Milan	<a href="#">Impact of breathing and image filtering on radiomic features extracted from 4D simulation CT in early stage NSCLC</a>

<b>P.64</b>	<b>Volpe</b>	<b>Stefania</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano; Department of Oncology and Hemato-Oncology, University of Milan	<a href="#">Computed tomography-based radiomics in oropharyngeal cancerpatients treated with radiotherapy: A promising tool for outcome modeling</a>
<b>P.65</b>	<b>De Benedictis</b>	<b>Ilaria</b>	Centro di Riferimento Oncologico IRCCS, Aviano	<a href="#">Multifocality of vascular tumors of bone: independent lesions or metastatic spreading?</a>
<b>P.66</b>	<b>De Vita</b>	<b>Alessandro</b>	Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori", Meldola	<a href="#">Advanced preclinical platforms to predict chemotherapy outcome in sarcoma: The key role of three-dimensional primary cultures and zebrafish models</a>
<b>P.67</b>	<b>Del Savio</b>	<b>Elisa</b>	Centro di Riferimento Oncologico IRCCS, Aviano	<a href="#">Molecular profiling unveils miRNA: gene circuitries that shape the clinicopathologic characteristics of epithelioid sarcomas</a>
<b>P.68</b>	<b>Laurino</b>	<b>Simona</b>	Centro di Riferimento Oncologico della Basilicata, IRCCS, Rionero in Vulture, Potenza	<a href="#">Radiation-Induced Sarcoma experience at the Basilicata Referral Cancer Center</a>
<b>P.69</b>	<b>Rota</b>	<b>Rossella</b>	Bambino Gesù Children's Hospital, IRCCS, Roma	<a href="#">A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo</a>

### SEPTEMBER 23<sup>rd</sup>

<b>P.01</b>	<b>Bergamaschi</b>	<b>Luca</b>	Division of Radiation Oncology, European Institute of Oncology IRCCS, Milano; Department of Oncology and Hemato-Oncology, University of Milan	<a href="#">Assessment of sarcopenia in oropharyngeal cancer patients treated with curative radiotherapy: time for a tailored approach?</a>
<b>P.02</b>	<b>Bochicchio</b>	<b>Anna Maria</b>	Centro di Riferimento Oncologico della Basilicata, IRCCS, Rionero in Vulture, Potenza	<a href="#">Thyroid carcinoma data at IRCCS-CROB, Rionero in Vulture: five years activity and new survivorship project.</a>
<b>P.03</b>	<b>Casirati</b>	<b>Amanda</b>	Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia	<a href="#">Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling</a>
<b>P.04</b>	<b>Casirati</b>	<b>Amanda</b>	Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia	<a href="#">Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations</a>
<b>P.05</b>	<b>Del Mistro</b>	<b>Annarosa</b>	Istituto Oncologico Veneto - IRCCS, Padova	<a href="#">Integration of primary and secondary strategies for cervical cancer prevention in the Veneto region</a>
<b>P.06</b>	<b>Ferrara</b>	<b>Paola Emilia</b>	Degenza e Servizi di Riabilitazione, Fondazione Policlinico Agostino Gemelli - IRCCS di Roma	<a href="#">Preliminary results of an integrated rehabilitative approach among pediatric oncology patients: a retrospective analysis</a>
<b>P.07</b>	<b>Pozzo</b>	<b>Carmelo</b>	Oncologia Medica Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma	<a href="#">Digital mobile or web-based cross platform application for cancer patients and oncology healthcare providers: a project of a new OncoCare</a>
<b>P.08</b>	<b>Rossi</b>	<b>Maria Maddalena</b>	Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma	<a href="#">"TILIA for insomnia during hormonal therapy in breast cancer survivors" - TILIA SHOT trial</a>
<b>P.09</b>	<b>Rupe</b>	<b>Cosimo</b>	Head and Neck Department, Fondazione Policlinico Universitario A. Gemelli—IRCCS, School of Dentistry, Università Cattolica del Sacro Cuore, Roma	<a href="#">Oral Candida colonization is a risk factor for severe oral mucositis in patients undergoing Radio-Chemotherapy for head &amp; neck cancer: results from a multidisciplinary mono-institutional prospective observational study</a>
<b>P.10</b>	<b>Serra</b>	<b>Patrizia</b>	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola	<a href="#">Integrative medicine in a comprehensive cancer center. A pilot experience</a>

## SUBMITTED ABSTRACTS

<b>P.11</b>	<b>Turrà</b>	<b>Valeria</b>	SSD Dietologia e Nutrizione Artificiale - Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli	Review of nutrition and cancer risk in gynecology
<b>P.12</b>	<b>Auciello</b>	<b>Francesca Romana</b>	Istituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena, Roma	Metabolism and tumour plasticity
<b>P.13</b>	<b>Bruzzese</b>	<b>Francesca</b>	Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Napoli	Multiparameter optimization and in vitro assessment of antagonists targeting androgen receptor's ligand binding domain and allosteric binding sites
<b>P.14</b>	<b>Castiglioni</b>	<b>Andrea</b>	Istituto Europeo di Oncologia, Milano	NCAM1 identifies a subpopulation of cancer-stem cells that predicts poor prognosis and ADT-resistance in prostate cancer
<b>P.15</b>	<b>D'Alessandro</b>	<b>Rosalba</b>	National Institute of Gastroenterology, "Saverio de Bellis" Research Hospital Castellana Grotte, Bari	Variations in circulating levels of Angiopoietin2 over time are predictive of Ramucirumab-Paclitaxel therapy outcome in advanced Gastric Cancer: Results of prospective study
<b>P.16</b>	<b>Figlioli</b>	<b>Carolina</b>	Genome Stability Group, Istituto Superiore di Sanità, Roma	Unscheduled activity of MUS81 confers resistance to PARP inhibitors in BRCA2-deficient cells
<b>P.17</b>	<b>Ghetti</b>	<b>Martina</b>	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori", Meldola	Effects of circPVT1 and linear PVT1 isoforms downregulation in acute myeloid leukemia cell lines
<b>P.18</b>	<b>Lepore Signorile</b>	<b>Martina</b>	Medical Genetics, National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari	Tailoring colorectal cancer stem cell-targeted therapy by inhibiting p38 $\alpha$ , the $\beta$ -catenin chromatin-associated kinase
<b>P.19</b>	<b>Musco</b>	<b>Lorena</b>	Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Pordenone	Exploring the response to radiotherapy plus targeted therapies in TP53WT vs TP53MUT head and neck squamous cell carcinoma
<b>P.20</b>	<b>Notarangelo</b>	<b>Tiziana</b>	Centro di Riferimento Oncologico della Basilicata - IRCCS-CROB, Rionero in Vulture, Potenza	STAT3 mediates resistance to cisplatin in gastric cancer
<b>P.21</b>	<b>Regazzo</b>	<b>Giulia</b>	Dept. of Research, Advanced Diagnostics and Technological Innovation.Oncogenomic and Epigenetic Unit-Translational Research Area, IRCCS Regina Elena National Cancer Institute, Roma	Genome wide analysis of microRNAs related to DLBCL resistance to immunochemotherapy in in vitro models
<b>P.22</b>	<b>Russi</b>	<b>Sabino</b>	IRCCS CROB Centro di Riferimento Oncologico della Basilicata	Double-side NEDD8 pathway targeting in p53-deficient gastric cancer cells
<b>P.23</b>	<b>Sanese</b>	<b>Paola</b>	IRCCS Saverio de Bellis-Ospedale Specializzato in Gastroenterologia, Castellana Grotte, Bari	SMYD3 inhibition impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance
<b>P.24</b>	<b>Schirizzi</b>	<b>Annalisa</b>	National Institute of Gastroenterology, "Saverio de Bellis" Research Hospital, Castellana Grotte, Bari	The combination of ramucirumab and elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
<b>P.25</b>	<b>Sistigu</b>	<b>Antonella</b>	Università Cattolica Del Sacro Cuore Policlinico Gemelli, Roma	Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
<b>P.26</b>	<b>Boutros</b>	<b>Andrea</b>	Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova	The predictive and prognostic role of single nucleotide gene variants in PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
<b>P.27</b>	<b>Comes</b>	<b>Maria Colomba</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	Disease-free survival prediction in melanoma patients by exploiting artificial intelligence techniques on melanoma whole slide images
<b>P.28</b>	<b>D'Aguzzo</b>	<b>Simona</b>	Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Roma	Investigating the predictive and prognostic role of Semaphorin5A in melanoma patients and its role in response to therapy
<b>P.29</b>	<b>Di Fonte</b>	<b>Roberta</b>	Istituto Tumori "Giovanni Paolo II" IRCCS Bari	Organotypic tumor cultures of metastatic melanoma for probing anti-PD1 based combination therapy
<b>P.30</b>	<b>Ferrucci</b>	<b>Pier Francesco</b>	European Institute of Oncology, IRCCS Milano	Meta-Analysis Of Randomized Trials Evaluating Triplet Combinations Of Immunotherapy And Targeted Therapy For BRAF V600-Mutant Unresectable Or Metastatic Melanoma

<b>P.31</b>	<b>Ferrucci</b>	<b>Pier Francesco</b>	European Institute of Oncology, IRCCS Milano	Clinical/translational study of neoadjuvant ipilimumab and nivolumab: clinical update with molecular and immunological biomarker's analysis in patients with locally advanced or oligometastatic melanoma
<b>P.32</b>	<b>Gaeta</b>	<b>Aurora</b>	Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milano	Meta-Analysis Of Randomized Trials Evaluating Triplet Combinations Of Immunotherapy And Targeted Therapy For BRAF V600-Mutant Unresectable Or Metastatic Melanoma
<b>P.33</b>	<b>Gaeta</b>	<b>Aurora</b>	Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milano	Reporting melanoma in Covid-era
<b>P.34</b>	<b>Noto</b>	<b>Francesco</b>	Istituto Superiore di Sanità, Roma	Epigenetic targeting of melanoma with Decitabine enhances the IL-33/ST2 axis and ameliorates the anti-tumoral activity of IL-33
<b>P.35</b>	<b>Serrati</b>	<b>Simona</b>	IRCCS Istituto Tumori Giovanni Paolo II, Bari	Circulating Extracellular Vesicles are biomarkers for the monitoring of anti-PD1 response in metastatic melanoma patients
<b>P.36</b>	<b>Valentini</b>	<b>Elisabetta</b>	Istituto Tumori Regina Elena IFO, Roma	Rationally derived drug combinations with inhibitors of Bcl-2 family proteins and target therapy in cancer models
<b>P.37</b>	<b>Vergani</b>	<b>Elisabetta</b>	Fondazione IRCCS Istituto Nazionale dei Tumori di Milano	Patient-derived tumor explant 3D cultures in bioreactor to improve immunotherapy in melanoma
<b>P.38</b>	<b>Affinito</b>	<b>Ornella</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma
<b>P.39</b>	<b>Bergamaschi</b>	<b>Luca</b>	Division of Radiotherapy, European Institute of Oncology, IRCCS, Milano	Radiosensitivity of Human Papilloma Virurs (HPV)-related tumors: towards a genomic approach – Mid-term analysis of the first year
<b>P.40</b>	<b>Buono</b>	<b>Lorena</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	Long non coding RNAs as and their role on the epigenome regulation as diagnostic markers in childhood acute lymphoblastic leukemia of T cells
<b>P.41</b>	<b>Colombo</b>	<b>Elena</b>	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Radecision: A three-clusters gene-expression landscape in cervical carcinoma to predict radiosensitivity
<b>P.42</b>	<b>De Matteis</b>	<b>Elisabetta</b>	Dipartimento di Ematologia ed Oncologia Azienda sanitaria locale, Lecce	Endometrial cancer and BRCA mutations in the salentinian population
<b>P.43</b>	<b>De Summa</b>	<b>Simona</b>	Istituto Tumori "Giovanni Paolo II" IRCCS, Bari	UNIC-MERKEL: transcriptomic evaluation in patients treated with immunotherapy
<b>P.44</b>	<b>Disciglio</b>	<b>Vittoria</b>	National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari	Identification and somatic characterization of the germline PTEN promoter variant rs34149102 in a family with gastrointestinal and breast tumors
<b>P.45</b>	<b>Ghiani</b>	<b>Lavinia</b>	European Institute of Oncology, Milano	Dissecting the role of the NSD2 histone methyltransferase in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
<b>P.46</b>	<b>Guidi</b>	<b>Eleonora</b>	IRCCS Ospedale San Raffaele, Milano	Technical optimization of whole-exome sequencing starting from archival FFPE clinical tumor samples: towards precision cancer medicine
<b>P.47</b>	<b>Melucci</b>	<b>Elisa</b>	Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma	A next generation sequencing panel analysis: a potential tailored tool for Gastric Cancer?
<b>P.48</b>	<b>Pane</b>	<b>Katia</b>	IRCCS- SYNLAB Istituto di diagnostica nucleare-SDN Research Institute Diagnostics and Nuclear, Napoli	Discovering common expression signatures underlying female-specific cancers via integrative computational approaches and machine learning
<b>P.49</b>	<b>Ricci</b>	<b>Angela Dalia</b>	Medical Oncology Unit, IRCCS Saverio de Bellis Hospital, Castellana Grotte, Bari	Molecular profiling and prognostic value of ATM Mutations in Intrahepatic Cholangiocarcinoma
<b>P.50</b>	<b>Sorino</b>	<b>Cristina</b>	IRCCS, Regina Elena National Cancer Institute, Roma	Enhancer plasticity sustains oncogenic transformation and progression of B-Cell acute lymphoblastic leukemia



The largest Italian cancer research network

[allianceagainstcancer.org](http://allianceagainstcancer.org) | [alleanzacontroilcancro.it](http://alleanzacontroilcancro.it)

